Kellett Joseph, Soliman Sara S, Podwojniak Alicia, Minkanic Michelle, Kumar Gaurav, Goodwin Brandon, Yang Hyo J, Elsawwah Jana K, Nemeth Zoltan H
Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, USA.
Department of Surgery, Morristown Medical Center, Morristown, NJ, USA.
Obes Surg. 2025 Mar;35(3):1127-1134. doi: 10.1007/s11695-025-07723-w. Epub 2025 Feb 5.
Metabolic and bariatric surgery (MBS) is a successful surgical option for obesity. However, many patients can experience insufficient weight loss and weight regain post-operatively. Glucagon-like peptide-1 (GLP-1) receptor agonists have become available for effective weight loss treatment due to their effects of suppressing appetite, slowing gastric emptying, and promoting fat loss. This systematic review aims to evaluate the efficacy of using GLP-1 agonists to treat insufficient weight loss or regain after metabolic/bariatric surgery. Pooled analysis demonstrated that GLP-1 agonists have a moderate effect on weight loss after failed weight loss or weight regain following MBS, with a Cohen's d-score of 0.470 (p ≤ 0.001). GLP-1 agonists show promise and deserve additional research as part of the standard of care following MBS with insufficient weight loss.
代谢与减重手术（MBS）是治疗肥胖的一种成功的手术选择。然而，许多患者术后可能会出现体重减轻不足和体重反弹的情况。胰高血糖素样肽-1（GLP-1）受体激动剂因其具有抑制食欲、减缓胃排空和促进脂肪减少的作用，已成为有效的减重治疗药物。本系统评价旨在评估使用GLP-1激动剂治疗代谢/减重手术后体重减轻不足或反弹的疗效。汇总分析表明，GLP-1激动剂对MBS术后体重减轻失败或体重反弹后的体重减轻有中等程度的影响，科恩d值为0.470（p≤0.001）。GLP-1激动剂显示出前景，作为MBS术后体重减轻不足的标准治疗的一部分，值得进一步研究。
